CD79A and neoplasm: In the TME, B cells are closely associated with tertiary lymphoid structures (TLS), and B cells in mature TLS can differentiate into plasma cells that produce immunoglobulin (Ig)G or IgA antibodies against tumor-associated antigens, exerting an anti-tumor effect that is correlated with a better clinical outcome and immunotherapeutic response in patients [18].